Диссертация (1139468), страница 33
Текст из файла (страница 33)
и др. // Клиническаямедицина. - 2013. - № 1. - С. 16-20.74.Шевелев В.И., Антигипертензивная терапия идинамикапоказателей ригидности сосудистой стенки у пожилых больных снеклапанной фибрилляции предсердий / Шевелев В.И., Канорский С.Г. //Клиническая медицина. -2012. - № 9. -С. 59-63.75.ШиловА.М.Патофизиологияипринципылеченияфибрилляции предсердий / Шилов А.М.
и др. // Русский МедицинскийЖурнал. – 2011. – №.14. – C.877–883.76.Шишкова В.Н. Хроническая болезнь почек и сердечно-сосудистая заболеваемость: фокус на фибрилляцию предсердий / Шишкова230В.Н. // Рациональная фармакотерапия в кардиологии – 2015.- №2.- С.196201.77.AFFIRM Investigators. A comparison of rate control and rhythmcontrol in patients with atrial fibrillation. // N Engl J Med- 2002-Vol.347-P.18251833.78.Allessie M. Electrical, contractile and structural remodeling duringatrial fibrillation.
/ Allessie M. [et al]// Cardiovasc Res/- 2002- Vol.54- P.230–46.79.Allessie MA. Pathophysiology and prevention of atrial fibrillation./Allessie MA [et al.]// Circulation. -2001.-Vol 103-P.769–777.80.Almroth H. Atorvastatin and persistent atrial fibrillation followingcardioversion: a randomized placebocontrolled multicentre study. / Almroth H.[et al.]// Eur Heart J – 2009-Vol 30- P.827–833.81.Alonso A.
Simple risk model predicts incidence of atrial fibrillationin a racially and geographically diverse population: the CHARGE-AFconsortium. / Alonso A. [et al.]// J Am Heart Assoc -2013-vol. 2- e000102.82.Alonso A Chronic kidney disease is associated with the incidence ofatrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. /Alonso A.
[et al.]// Circulation.- 2011-Vol. 123-P.2946-53.83.Ammash N. Left atrial blood stasis and Von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation./ Ammash N. [et al.]// ArteriosclerThromb Vasc Biol.- 2011- Nov 31-Vol. 11-P.2760-6.84.Anand K. Meta-analysis: inhibition of renin-angiotensin systemprevents new-onset atrial fibrillation./ Anand K. [et al.]// Am Heart J. -2006Vol152-P.217-22.85.Apostolakis S. Comparison of the CHADS2, CHA2DS2 -VASc andHAS-BLED scores for the prediction of clinically relevant bleeding inanticoagulated patients with atrial fibrillation: The AMADEUS trial.
/Apostolakis S. [et al.]// Thromb Haemost -2013- Vol 110- P.1074-9.23186.Aslanidi OV. 3D virtual human atria: A computational platform forstudying clinical atrial fibrillation. / Aslanidi OV. [et al.]//Progress inBiophysics and Molecular Biology – 2011- Vol 107(1)- P.156–168.87.Asselbergs FW. C-reactive protein and microalbuminuria areassociated with atrial fibrillation. / Asselbergs FW. [et al.]// Int J Cardiol. - 2005Vol 98(1)- P.73-7.88.Auer J. Subclinical hyperthyroidism as a risk factor for atrialfibrillation. / Auer J. [et al.]// Am Heart J.
-2001- Vol 142(5)- P.838–842.89.Aviles R.J. Inflammation as a risk factor for atrial fibrillation./Aviles R.J. [et al.]// Circulation. -2003 – Vol 108(24)-P.3006-10.90.Badheka A.O. Optimal blood pressure in patients with atrialfibrillation (from the AFFIRM Trial). /Badheka A.O. [et al.]// Am.
J. Cardiol.2014 – Vol 114(5)- P.727-36.91.Barrett T.W. Evaluating the HATCH score for predicting progressionto sustained atrial fibrillation in ED patients with new atrial fibrillation./ BarrettT.W. [et al.]// The American Journal of Emergency Medicine- 2013- Vol 31(5)P.792–797.92.BayturanO.Atrialfibrillation,progressionofcoronaryatherosclerosis and myocardial infarction. / Bayturan O. [et al.]// Eur J PrevCardiol. -2017 –Vol. 24(4)- P.373-381.93.Belluzzi F.
Prevention of recurrent lone atrial fibrillation by theangiotensin-II converting enzyme inhibitor ramipril in normotensive patients. /Belluzzi F. [et al.]// J Am Coll Cardiol – 2009- Vol 53- P.24 –9.94.Benjamin EJ. Independent risk factors for atrial fibrillation in apopulation-based cohort. The Framingham Heart Study.
/ Benjamin EJ. [et al.]//JAMA. -1994 – Vol 271(11)- P.840-4.95.Benjamin EJ. Impact of atrial fibrillation on the risk of death: theFramingham Heart Study. / Benjamin EJ. [et al.]// Circulation -1998- Vol98P.946–52.23296.Berruezo, A. Pre-procedural predictors of atrial fibrillationrecurrence after circumferential pulmonary vein ablation.
/ Berruezo A. [et al.]//A. Eur Heart J. – 2007- Vol 28- P.836–841.97.Bisbal, F. Left atrial sphericity: a new method to assess atrialremodeling. Impact on the outcome of atrial fibrillation ablation. / Bisbal, F. [etal.]// J Cardiovasc Electrophysiol. -2013- Vol 24-P.752–759.98.Bisbal, F. Left atrial geometry improves risk prediction ofthromboembolic events in patients with atrial fibrillation./ Bisbal, F.
[et al.]//JCardiovasc Electrophysiol. – 2016-Vol 27- P.804–810.99.Blana A. Knock-in gain-of-function sodium channel mutationprolongs atrial action potentials and alters atrial vulnerability. / Blana A. [et al.]//Heart Rhythm. – 2010.- Vol 7(12)- P.1862–1869.100. Boldt A. Expression of angiotensin II receptors in human left andright atrial tissue in atrial fibrillation with and without underlying mitral valvedisease./ Boldt A. [et al.]// J Am Coll Cardiol. - 2003 – Vol 42(10)- P.1785-92.101. Bonhorst D.
Prevalence of atrial fibrillation in the Portuguesepopulation aged 40 and over: the FAMA study. / Bonhorst D. [et al.]//Rev PortCardiol. - 2010 – Vol 29(3)- p.331-50102. Bos MJ. Decreased glomerular filtration rate is a risk factor forhemorrhagic but not for ischemic stroke: the Rotterdam Study. / Bos MJ. [et al.]//Stroke – 2007- Vol 38- P.3127-32.103. Buch P.
Reduced lung function and risk of atrial fibrillation in theCopenhagen City Heart Study. / Buch P. // Eur Resp J – 2003- Vol 21-P. 1012-6.104. Bukowska A. Atrial fibrillation down-regulates renal neutralendopeptidase expression and induces profibrotic pathways in the kidney./Bukowska A. [et al.]// Europace – 2008- Vol 10(10)- P. 1212–7.105. Burstein B. Atrial fibrosis: mechanisms and clinical relevance inatrial fibrillation./ Burstein B. [et al.]// J Am Coll Cardiol.- 2008 Vol 51(8)P.802–809.233106. Caldeira D. Rate versus rhythm control in atrial fibrillation andclinical outcomes: updated systematic review and meta-analysis of randomizedcontrolled trials / Caldeira D.
[et al.]// Arch Cardiovasc Dis. -2012 –Vol 105P.226–238.107. Calkins H. 2012 HRS/EHRA/ECAS expert consensus statement oncatheter and surgical ablation of atrial fibrillation. / Calkins H. [et al.]// HeartRhythm – 2012- Vol 9- P.632–96.108. Calo L. N-3 Fatty acids for the prevention of atrial fibrillation aftercoronary artery bypass surgery: a randomized, controlled trial.
/ Calo L. [et al.]//J Am Coll Cardiol – 2005- Vol 45- P.1723-1728.109. Camm A.J. Atrial fibrillation and risk./ Camm A.J. // ClinCardiol2012- Vol 35 Suppl 1- P.1-12110. Camm A.J. Real-life observations of clinical outcomes with rhythmand rate-control therapies for atrial fibrillation RECORDAF. / Camm A.J. [etal.]// J Am Coll Cardiol – 2011- Vol 58- P.493–501.111. Camm AJ. Guidelines for the management of atrial fibrillation: theTask Force for the Management of Atrial Fibrillation of the European Society ofCardiology (ESC)./ Camm AJ. [et al.]// Eur Heart J- 2010- Vol 31- P.2369–429.112. Camm AJ. Guidelines for the management of atrial fibrillation./Camm A.J. [et al.]// European Heart Journal.- 2010- Vol 31(19)- P.2369–2429.113.
Carlsson J. STAF Investigators. Randomized trial of rate-controlversus rhythm-control in persistent atrial fibrillation./ Carlsson J. [et al.]// J AmColl Cardiol – 2003- Vol 41- P.1690-1696.114. Celermajer D.S. Non-invasive detection of endothelial disfunctionin children and adult at risk of atherosclerosis / Celermajer D.S. [et al.]// Lancet.— 1992. — Vol. 340. — P. 1111–1115.115. Chamberlain AM, A clinical risk score for atrial fibrillation in abiracial prospective cohort (from the Atherosclerosis Risk in Communities234[ARIC] study).
/ Chamberlain AM. [et al.]// Am J Cardiol 2011 – Vol 107 –P.85–91.116. Charitos EI, Clinical classifications of atrial fibrillation poorly reflectits temporal persistence: Insights from 1,195 patients continuously monitoredwith implantable devices. / Charitos E.I. [et al.]// Journal of the American Collegeof Cardiology. – 2014 – Vol 63- P. 2840–2848.117. Charitos EI, Atrial fibrillation density: A novel measure of atrialfibrillation temporal aggregation for the characterization of atrial fibrillationrecurrence pattern.
/ Charitos EI. [et al.]// Applied CardiopulmonaryPathophysiology. – 2013- Vol 17(1)- P.3–10.118. Chen L.Y. Epidemiology of atrial fibrillation: a current perspective/Chen L.Y. [et al.]// Heart Rhythm. -2007 –Vol 4(3 Suppl)- S1-6.119. Chen S. Should rhythm control be preferred in younger atrialfibrillation patients?/ Chen S. [et al.]// J Interv Card Electrophysiol. – 2012.-Vol22- P.34-39.120. Choi EK Intrinsic cardiac nerve activity and paroxysmal atrialtachyarrhythmia in ambulatory dogs./ Choi EK [et al.]// Circulation. 2010 –Vol121(24)- P.2615–2623.121. Chou CC. New concepts in atrial fibrillation: neural mechanisms andcalcium dynamics./ Chou CC, Chen PS.
// Cardiol Clin. – 2009- Vol 27(1)- P.35–43.122. Chou CC. Intracellular calcium dynamics and acetylcholine-inducedtriggered activity in the pulmonary veins of dogs with pacing-induced hearfailure. / Chou CC. [et al.]// Heart Rhythm. – 2008 –Vol 5(8)- P. 1170–1177.123. Chua SK. Renal dysfunction and the risk of postoperative atrialfibrillation after cardiac surgery: role beyond the CHA2DS2-VASc score. / ChuaSK.
[et al.]// Europace – 2015 – Vol 17- P.1363–70.235124. Chugh SS. Worldwide epidemiology of atrial fibrillation: a GlobalBurden of Disease 2010 Study. / Chugh SS. [et al.]// Circulation – 2014- Vol129- P.837–47.125. Colman M.A. Pro-arrhythmogenic effects of atrial fibrillationinduced electrical remodelling: insights from the three-dimensional virtual humanatria. / Colman M.A. [et al.]// The Journal of Physiology – 2013- Vol 591(17)P.4249–72.126. Corley SD. Relationships between sinus rhythm, treatment, andsurvival in the Atrial Fibrillation Follow-Up Investigation of RhythmManagement (AFFIRM) Study./ Corley SD.
[et al.]// Circulation 2004- Vol 109P.1509–13.127. Guidelines for management of atrial fibrillation. The task force forthe management of Atrial Fibrillation of European Society of Cardiology (ESC)// Eur. Heart J. – 2013- Vol 31 (19)- P. 2369-439.128. Darby A. Management of atrial fibrillation in patients with structuralheart disease/ Darby A. [et al.] // Circulation.
– 2012. – Vol. 125. – P. 945–957.129. De Vos CB. Progression of atrial fibrillation in the REgistry onCardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort:clinical correlates and the effect of rhythm-control therapy. / De Vos CB. [et al.]// Am Heart J - 2012- Vol 163- P.887–93.130. De Vos C.B. Progression from paroxysmal to persistent atrialfibrillation clinical correlates and prognosis./ De Vos CB.
[et al.] // J Am CollCardiol – 2010- Vol 55- P.725–31.131. De Vos CB. The mechanical fibrillation pattern of the atrialmyocardium is associated with acute and long-term success of electricalcardioversion in patients with persistent atrial fibrillation/ De Vos CB. [et al.] //Heart Rhythm.–2014- Vol 11(9)- P.1514-21.236132. Dhein S. Improving cardiac gap junction communication as a newantiarrhythmic mechanism: the action of antiarrhythmic peptides.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
